@isth.org

How do you manage oral anticoagulants in patients undergoing an invasive dental procedure?
Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding!
@RPTHjournal

doi.org/10.1016/j.rp...

Extended anticoagulant therapy with reduced-dose apixaban was noninferior to full-dose in patients with active cancer and #cvVTE, based on findings from the API-CAT trial presented at #ACC25.

Read the journal scan to learn more: bit.ly/43w2A8v

#CardioSky #MedSky

A graph showing the cumulative incidence of recurrent venous thromboembolism (primary efficacy outcome) among patients who received apixaban at a reduced (2.5 mg) or full (5.0 mg) dose twice daily for 12 months.

In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full results: nej.md/41YkRZK

#ACC25 | @accintouch.bsky.social

The New England Journal of Medicine Extended Reduced-Dose Apixaban for Cancer-Associated VTE A Research Summary based on Mahé I et al. | 10.1056/NEJMoa2416112 | Published on March 29, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary: nej.md/41YkRZK

#MedSky

#API-CAT study by the #nejm.org.
#accintouch.bsky.social #isth.org
#apixaban #VTE #cancer

Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months... Reduced-Dose Apixaban for Cancer-Associated VTE (API-CAT Trial) | NEJM

Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months. Findings from the API-CAT trial are summarized in a short video.

#API-CAT study by the @nejm.org.
@accintouch.bsky.social @isth.org
#apixaban #VTE #cancer

#APICAT trial at #ACC25 #LBCT #cardioonc

🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths

Une étude majeure dans la prise en charge des patients atteints de cancer et traités pour un événement thromboembolique veineux, deuxième cause de décès, a été menée et coordonnée par la Pr Isabelle Mahé, cheffe du service de médecine interne de @hoplouismourier.bsky.social
A découvrir ici 👇

🔬 Pour la première fois, une étude démontre que la dose réduite d'un anticoagulant oral est aussi efficace que la dose pleine et réduit le risque hémorragique de 25% pour les patients atteints de #cancer traités pour thrombose veineuse ou embolie pulmonaire

Découvrez les résultats 👉 swll.to/sOSmEZC

@acc25.bsky.social Isabelle Mahe presents API-CAT
Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win!

Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE

#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism | NEJM In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and dec...

Finally! More data to add to the EVE trial

APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)

#Hemesky #BSH

www.nejm.org/doi/full/10....

@acc2025.bsky.social @jaccjournals.bsky.social

The article published in the @NEJM.org can be accessed.see below

Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112

Prof. @isabellemahe.bsky.social presents API-CAT at @accintouch.bsky.social published in @nejm.org: Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in cancer patients
www.nejm.org/doi/full/10....

Regulatory agencies have issued warnings about JAK inhibitors and VTE risk—but what does the evidence actually say?

Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social

📑 Read now: buff.ly/4ijJQNq

The #VTE risk associated with #JAKi in #inflammatory diseases has been suggested, followed by precautionary measures by health authorities. This literature review illustrates that available data on VTE risk on JAKi are conflicting and inconclusive
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...